MCK: Analyst Upgrades Clash with Persistent Options Caution

McKesson heads into the back half of August with a notable split between what the Street is saying and what options traders are doing — a divergence worth watching closely after a week that saw the stock slip 3.6% to $869.26.

The analyst picture has turned decisively more constructive. Barclays raised its target to $1,000 from $925 today, maintaining Overweight, while RBC Capital initiated fresh coverage at Sector Perform with an $845 target. That follows a string of post-earnings target lifts: UBS bumped to $1,080, Evercore ISI moved to $1,000, and TD Cowen raised to $1,006 — all within the past two weeks. The consensus sits at Hold with a mean target near $987, implying roughly 13.5% upside from current levels. Bulls point to McKesson's dominant position in pharmaceutical distribution and its oncology channel exposure. Bears — RBC among them with its below-consensus $845 target — are more cautious on near-term margin expansion given generic pricing pressure and the looming threat from healthcare supply chain disruptors.

Options positioning tells a more defensive story, and it has not resolved the way yesterday's note flagged it might. The put/call ratio eased fractionally to 0.609 from 0.617 on Monday, but remains nearly two standard deviations above its 20-day mean of 0.537. That is the second-highest defensive reading of the past year. The PCR was running near 0.501 at the start of August, just before earnings. The post-earnings relief rally was brief; hedging demand crept back almost immediately and has been sticky since.

Short interest has eased slightly — down about 1.2% in the latest session to 2.93% of free float — but the weekly picture still shows an 8% build from the August 10 trough. That is consistent with shorts rebuilding positions after covering into the earnings beat. Crucially, the borrow market continues to send a contradictory signal: availability is exceptionally loose at over 8,400% of short interest, and cost to borrow has dropped sharply, now running at just 0.30% annually — less than half its level from earlier in the month. With shares so easily and cheaply sourced, the short rebuild looks opportunistic rather than conviction-driven. There is no squeeze pressure in the lending market whatsoever.

Institutional ownership is broadly stable. JP Morgan Asset Management added 425,501 shares through July, a notable accumulation. Arrowstreet built 239,786 shares in the quarter through June. BlackRock and State Street each added modestly. On the insider side, the pattern has been one-directional: CEO Brian Tyler sold shares three times between early June and early July, totalling roughly $17 million in proceeds, at prices ranging from $763 to $794 — well below today's $869 level. That sequence preceded a meaningful re-rating, though the sales themselves were disclosed at low-significance levels and are consistent with planned disposal programs.

The next scheduled earnings event is November 4. What to watch between now and then is whether the put/call ratio, which has been elevated and sticky since mid-August, begins to unwind as the share price stabilises — or whether the options caution deepens further on any deterioration in the healthcare policy backdrop, particularly around Medicaid reimbursement rates and specialty drug channel dynamics.